[go: up one dir, main page]

WO2022036033A3 - Solid state forms of an organic compound - Google Patents

Solid state forms of an organic compound Download PDF

Info

Publication number
WO2022036033A3
WO2022036033A3 PCT/US2021/045656 US2021045656W WO2022036033A3 WO 2022036033 A3 WO2022036033 A3 WO 2022036033A3 US 2021045656 W US2021045656 W US 2021045656W WO 2022036033 A3 WO2022036033 A3 WO 2022036033A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid state
state forms
organic compound
forms
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/045656
Other languages
French (fr)
Other versions
WO2022036033A2 (en
WO2022036033A4 (en
Inventor
Jose Luis RIOS LIZARRAGA
Kristopher Depew
Louis Grenier
Benjamin S. Lane
Eric Simone
Jacob Paul SIZEMORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servier Pharmaceuticals LLC
Original Assignee
Servier Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Pharmaceuticals LLC filed Critical Servier Pharmaceuticals LLC
Publication of WO2022036033A2 publication Critical patent/WO2022036033A2/en
Publication of WO2022036033A3 publication Critical patent/WO2022036033A3/en
Publication of WO2022036033A4 publication Critical patent/WO2022036033A4/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Provided herein are various solid state forms, including salts as well as various crystalline and amorphous forms, of Compound I which is represented by the structural formula: Also provided are pharmaceutical compositions comprising these materials, methods for their manufacture, uses thereof for treating conditions, including but not limited to conditions that would benefit from inhibition of methionine adenosyltransferase 2a (MAT2A).
PCT/US2021/045656 2020-08-12 2021-08-12 Solid state forms of an organic compound Ceased WO2022036033A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063064866P 2020-08-12 2020-08-12
US63/064,866 2020-08-12

Publications (3)

Publication Number Publication Date
WO2022036033A2 WO2022036033A2 (en) 2022-02-17
WO2022036033A3 true WO2022036033A3 (en) 2022-04-21
WO2022036033A4 WO2022036033A4 (en) 2022-06-23

Family

ID=77693586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/045656 Ceased WO2022036033A2 (en) 2020-08-12 2021-08-12 Solid state forms of an organic compound

Country Status (3)

Country Link
AR (1) AR123228A1 (en)
TW (1) TW202227446A (en)
WO (1) WO2022036033A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116987084A (en) * 2022-04-26 2023-11-03 上海交通大学 Pyrazolopyrimidine compound and salt, solvate, composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014407A1 (en) * 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
WO2015138837A1 (en) * 2014-03-14 2015-09-17 Agios Pharmaceuticals, Inc Pharmaceutical compositions of therapeutically active compounds
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190761A1 (en) 2016-08-31 2019-06-05 Agios Pharmaceuticals Inc CELLULAR METABOLIC PROCESS INHIBITORS
CN118359585A (en) 2017-11-02 2024-07-19 法国施维雅药厂 Co-crystals, pharmaceutical compositions thereof and methods of treatment involving same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014407A1 (en) * 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
WO2015138837A1 (en) * 2014-03-14 2015-09-17 Agios Pharmaceuticals, Inc Pharmaceutical compositions of therapeutically active compounds
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUN HEE LEE: "A practical guide to pharmaceutical polymorph screening & selection", ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 9, no. 4, 16 March 2014 (2014-03-16), NL, pages 163 - 175, XP055260946, ISSN: 1818-0876, DOI: 10.1016/j.ajps.2014.05.002 *

Also Published As

Publication number Publication date
AR123228A1 (en) 2022-11-09
WO2022036033A2 (en) 2022-02-17
WO2022036033A4 (en) 2022-06-23
TW202227446A (en) 2022-07-16

Similar Documents

Publication Publication Date Title
SA522433155B1 (en) Trisubstituted ring compounds
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
JOP20210301A1 (en) Condensed tryciclic pyrroles as alpha-1 antitrypsin modulators
CA2875877C (en) Syk inhibitors
MX2020007265A (en) RAPAMYCIN DERIVATIVES.
BRPI1009333B8 (en) beta-secretase inhibitor compounds, their uses, as well as pharmaceutical composition
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
SA523451905B1 (en) Substituted Pyrimidinyl-Pyrazoles as CDK2 Inhibitors
MY209839A (en) Oxadiazole transient receptor potential channel inhibitors
UA89123C2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2021001804A (en) UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS.
PH12022551523A1 (en) Cyclic compounds and methods of using same
WO2020132471A8 (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
MX2025000635A (en) Cyclic compounds and methods of using same
PH12020552185A1 (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
MX2024012967A (en) PYRIDINE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
WO2022036033A3 (en) Solid state forms of an organic compound
WO2023150291A3 (en) Heterocyclic compounds and methods of use
MX2025006291A (en) Methods of treating neurological disorders
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP4397366A3 (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
MX2024006176A (en) Naphthyridinone derivatives for the treatment of a disease or disorder.
WO2023049808A3 (en) Small molecule inhibitors of tead-yap

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21766748

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21766748

Country of ref document: EP

Kind code of ref document: A2